Documents obtained by Rep. Waxman undercut FDA’s claim that the Plan B application raised “novel” issues requiring extended additional analysis.
Committee On Oversight and Government Reform
U.S. House of Representatives | 2157 Rayburn House Office Building | Washington, D.C. 20515 | (202) 225-5051